Abstract:Abstract Background: Ovarian cancer is the leading cause of gynecological cancer-related mortality. The majority of patients have poor prognosis due to the lack of available biomarkers capable of predicting prognosis accurately and providing novel targeted therapy options. Methods: The methylation array data, gene expression profile and clinical information of 351 ovarian serous cystadenocarcinoma (OSC) samples as well as the methylation array data of another 10 normal ovarian epithelial tissues were accessed from The Cancer Genome Atlas (TCGA) and served as training dataset. An algorithm, MethylMix, was on the basis of a β mixture model to compare the DNA methylation status in tumor to normal DNA methylation status and then screened out hypo and hypermethylated genes of OSC, which were transcriptionally predictive. Gene Ontology (GO) enrichment and ConsensusPathDB pathway analysis of differential methylation-driven genes were further performed. A linear risk model was constructed through the univariate and multivariate COX regression with Akaike Information Criterion (AIC). Datasets of OSC from Gene Expression Omnibus (GEO) database were served as validation datasets to determine the prognostic value of the risk model. The Kaplan-Meier analysis was then used to evaluate the ability of the risk model to distinguish the survival in training dataset or validation dataset, even in subgroups of patients with different FIGO stage, histologic grade, residual tumor after surgery, and anatomic neoplasm subdivision. The receiver operating characteristic (ROC) curve was also applied to determine the value of risk model on predicting the prognostic survival of patients as well as compared with other 15 known prognostic biomarkers in OSC. Results: Totally 171 differential methylation-driven genes were identified between OSC and normal samples. Five of them, UBB , PLAT , TMOD1 , KCNJ11 , and CDSN , were selected to construct the prognostic risk model. The Kaplan-Meier analysis demonstrated that the survival rate in low-risk cohort was significantly higher than that in high-risk cohort in both training dataset and validation dataset ( P <0.0001 for training dataset; P <0.05 for validation dataset). Further, the ROC analysis confirmed the prognosis-predict value of the risk model applicable not only in different group of patients but also more accurately when compared with other biomarkers. Conclusions: Our study successfully identified multiple methylation-driven genes in OSC and constructed a novel prognostic risk model to provide bioinformatic basis and an important tool for guiding subsequent OSC early diagnosis, prognosis assessment, and clinical treatment.

A Gene Signature Driven by Abnormally Methylated DEGs Was Developed for TP53 Wild-Type Ovarian Cancer Samples by Integrative Omics Analysis of DNA Methylation and Gene Expression Data

Development and Validation of a Prognostic Nomogram Based on DNA Methylation-Driven Genes for Patients With Ovarian Cancer

Identification and validation of immunity- and disulfidptosis-related genes signature for predicting prognosis in ovarian cancer

Exploration of differential methylation-driven genes to identify key epigenetic genes for prognosis of ovarian serous cystadenocarcinoma

Integrated analysis of gene expression and DNA methylation profiles in ovarian cancer

Development of a Five-Gene Signature As a Novel Prognostic Marker in Ovarian Cancer

Identification and validation of a 9-gene signature for the prognosis of ovarian cancer by integrated bioinformatical analysis

A risk model of gene signatures for predicting platinum response and survival in ovarian cancer

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis Prediction in Ovarian Cancer.

Immune-related gene methylation prognostic instrument for stratification and targeted treatment of ovarian cancer patients toward advanced 3PM approach

Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis

An EMT-based Gene Signature Enhances the Clinical Understanding and Prognostic Prediction of Patients with Ovarian Cancers

Comprehensive Analysis of DNA Methylation and Transcriptome to Identify PD-1-Negative Prognostic Methylated Signature in Endometrial Carcinoma.

Integrative Analysis of Identifying Methylation-Driven Genes Signature Predicts Prognosis in Colorectal Carcinoma

Prognostic and therapeutic prediction by screening signature combinations from transcriptome–methylome interactions in oral squamous cell carcinoma

A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma

Identification of Tumor Microenvironment and DNA Methylation-Related Prognostic Signature for Predicting Clinical Outcomes and Therapeutic Responses in Cervical Cancer

A methylation- and immune-related lncRNA signature to predict ovarian cancer outcome and uncover mechanisms of chemoresistance

A nine-gene signature related to tumor microenvironment predicts overall survival with ovarian cancer

Investigation of Aberrantly Methylated Differentially Expressed Genes in Pancreatic Cancer by Integrated Bioinformatics Analysis

Predicting Panel of Metabolism and Immune-Related Genes for the Prognosis of Human Ovarian Cancer.